Lauren S. Kramer

In recognition of her work, Ms. Kramer was named one of Best Lawyers’ Ones To Watch in America.

Ms. Kramer’s select representations include:

• Honeywell in its:
  • announced plan to spin off its advanced materials business
  • $4.95 billion acquisition of the global access solutions business of Carrier Global Corporation
  • $1.3 billion acquisition of Sparta Systems from New Mountain Capital
• Berry Global Group, Inc. in its pending $37 billion merger with Amcor
• Air Products and Chemicals, Inc. in the $1.81 billion sale of its liquefied natural gas (LNG) process technology and equipment business to Honeywell
• Keurig Dr Pepper in its strategic partnership and $300 million investment in La Colombe Coffee Roasters
• Activision Blizzard Inc. in its $75 billion acquisition by Microsoft Corporation
• Genesys, a portfolio company of the Permira Funds and Hellman & Friedman, in a $580 million round of funding at a valuation of $21 billion
• Spotify Technology S.A. in its (i) acquisition of Chartable Holding Inc. and (ii) acquisition of Megaphone LLC from Graham Holdings
• OceanSound Partners and its portfolio company Netrix in the acquisition of the managed IT services business unit of Contegix, LLC
• Vital Proteins in its acquisition by Nestlé Health Science
• Mubadala Investment Company in its investment as part of a consortium of $2.25 billion in Waymo
• NXP Semiconductors N.V. in its:
  • $1.8 billion acquisition of Marvell Technology Group Ltd.’s wireless connectivity portfolio
  • proposed (but terminated) $47 billion acquisition by Qualcomm Incorporated
• Permira Funds in several transactions, including:
  • the sale of its portfolio company LSNE to PCI Pharma Services
  • its acquisition of a majority stake in Axiom
  • its acquisition of a majority stake in Reformation
  • its acquisition of a majority stake in Cielo, Inc. from Accel-KKR
  • the $2.3 billion sale of its portfolio company Atrium Innovations to Nestlé S.A.
• Goldman Sachs & Co. as financial advisor in several transactions, including:
  • Turning Point Therapeutics, Inc. in its $4.1 billion sale to Bristol-Myers Squibb Company
  • Covetrus, Inc. in its $4 billion sale to funds affiliated with Clayton, Dubilier & Rice and TPG Capital